Covered recipient · General Payments record
PHILIP SCHOENFELD
General Payments · PY2018–2024
$4,571.55
- Reported across 110 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $489.56 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $135.06 | 6 |
| Galderma Laboratories, L.P. | $77.33 | 2 |
| GlaxoSmithKline, LLC. | $63.34 | 2 |
| Medtronic, Inc. | $57.74 | 1 |
| REVANCE THERAPEUTICS, INC. | $52.12 | 1 |
| Regeneron Healthcare Solutions, Inc. | $28.61 | 1 |
| OptiNose US, Inc. | $28.35 | 1 |
| AERIN MEDICAL INC. | $25.16 | 1 |
| Stryker Corporation | $21.85 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $23.77 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106039670 | CMS |
| ABBVIE INC. | $17.98 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106039672 | CMS |
| ABBVIE INC. | $25.31 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106039674 | CMS |
| ABBVIE INC. | $25.33 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106039676 | CMS |
| ABBVIE INC. | $23.49 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106039678 | CMS |
| ABBVIE INC. | $19.18 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106039680 | CMS |
| AERIN MEDICAL INC. | $25.16 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144651092 | CMS |
| Galderma Laboratories, L.P. | $39.09 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145326758 | CMS |
| Galderma Laboratories, L.P. | $38.24 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145326760 | CMS |
| GlaxoSmithKline, LLC. | $31.62 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116594130 | CMS |
| GlaxoSmithKline, LLC. | $31.72 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116215874 | CMS |
| Medtronic, Inc. | $57.74 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116883128 | CMS |
| Optinose US, Inc. | $28.35 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142186212 | CMS |
| Regeneron Healthcare Solutions, Inc. | $28.61 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114162514 | CMS |
| REVANCE THERAPEUTICS, INC. | $52.12 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147928757 | CMS |
| Stryker Corporation | $21.85 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126812627 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.